The stock of Sangamo Therapeutics Inc (NASDAQ: SGMO) has decreased by -0.50 when compared to last closing price of 2.01.Despite this, the company has seen a loss of -15.25% in its stock price over the last five trading days. businesswire.com reported 2024-11-19 that RICHMOND, Calif.–(BUSINESS WIRE)–SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR ST-503 FOR THE TREATMENT OF IDIOPATHIC SMALL FIBER NEUROPATHY.
Is It Worth Investing in Sangamo Therapeutics Inc (NASDAQ: SGMO) Right Now?
Company’s 36-month beta value is 1.18.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 4 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SGMO is 199.07M, and currently, short sellers hold a 6.73% ratio of that floaft. The average trading volume of SGMO on December 10, 2024 was 7.39M shares.
SGMO’s Market Performance
SGMO stock saw a decrease of -15.25% in the past week, with a monthly decline of -28.83% and a quarterly a decrease of 132.29%. The volatility ratio for the week is 10.82%, and the volatility levels for the last 30 days are 13.32% for Sangamo Therapeutics Inc (SGMO). The simple moving average for the past 20 days is -6.48% for SGMO’s stock, with a 115.93% simple moving average for the past 200 days.
Analysts’ Opinion of SGMO
Many brokerage firms have already submitted their reports for SGMO stocks, with RBC Capital Mkts repeating the rating for SGMO by listing it as a “Sector Perform.” The predicted price for SGMO in the upcoming period, according to RBC Capital Mkts is $2 based on the research report published on November 03, 2023 of the previous year 2023.
BofA Securities, on the other hand, stated in their research note that they expect to see SGMO reach a price target of $1.50, previously predicting the price at $5. The rating they have provided for SGMO stocks is “Underperform” according to the report published on April 28th, 2023.
Wedbush gave a rating of “Outperform” to SGMO, setting the target price at $16 in the report published on February 27th of the previous year.
SGMO Trading at 19.09% from the 50-Day Moving Average
After a stumble in the market that brought SGMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.09% of loss for the given period.
Volatility was left at 13.32%, however, over the last 30 days, the volatility rate increased by 10.82%, as shares sank -30.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +130.68% upper at present.
During the last 5 trading sessions, SGMO fell by -15.25%, which changed the moving average for the period of 200-days by +76.99% in comparison to the 20-day moving average, which settled at $2.14. In addition, Sangamo Therapeutics Inc saw 268.12% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SGMO
Current profitability levels for the company are sitting at:
- -2.57 for the present operating margin
- 0.85 for the gross margin
The net margin for Sangamo Therapeutics Inc stands at -2.58. The total capital return value is set at -1.97. Equity return is now at value -156.42, with -82.26 for asset returns.
Based on Sangamo Therapeutics Inc (SGMO), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at -4.12.
Currently, EBITDA for the company is -87.43 million with net debt to EBITDA at 0.09. When we switch over and look at the enterprise to sales, we see a ratio of 7.76. The receivables turnover for the company is 4.98for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.35.
Conclusion
In a nutshell, Sangamo Therapeutics Inc (SGMO) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
